Critical Behaviour of Non-Equilibrium Phase Transitions to Magnetically Ordered States

We describe non-equilibrium phase transitions in arrays of dynamical systems with cubic nonlinearity driven by multiplicative Gaussian white noise. Depending on the sign of the spatial coupling we observe transitions to ferromagnetic or antiferromagnetic ordered states. We discuss the phase diagram, the order of the transitions, and the critical behaviour. For global coupling we show analytically that the critical exponent of the magnetization exhibits a transition from the value 1/2 to a non-universal behaviour depending on the ratio of noise strength to the magnitude of the spatial coupling.Comment: 4 pages, 5 figure

The Lamb shift in muonic hydrogen and the proton radius

By means of pulsed laser spectroscopy applied to muonic hydrogen (μ− p) we have measured the 2S F = 1 1/2 − 2PF = 2 3/2 transition frequency to be 49881.88(76) GHz. By comparing this measurement with its theoretical prediction based on bound-state QED we have determined a proton radius value of rp = 0.84184 (67) fm. This new value is an order of magnitude preciser than previous results but disagrees by 5 standard deviations from the CODATA and the electronproton scattering values. An overview of the present effort attempting to solve the observed discrepancy is given. Using the measured isotope shift of the 1S-2S transition in regular hydrogen and deuterium also the rms charge radius of the deuteron rd = 2.12809 (31) fm has been determined. Moreover we present here the motivations for the measurements of the μ 4He + and μ 3He + 2S-2P splittings. The alpha and triton charge radii are extracted from these measurements with relative accuracies of few 10 − 4. Measurements could help to solve the observed discrepancy, lead to the best test of hydrogen-like energy levels and provide crucial tests for few-nucleon ab-initio theories and potentials

An economic evaluation of the randomized controlled trial of topical corticosteroid and home-based narrowband ultraviolet B for active and limited vitiligo (the HI-Light Vitiligo Trial)

Background: Economic evidence for vitiligo treatments is absent. Objectives: To determine the cost-effectiveness of (i) handheld narrowband ultraviolet B (NB-UVB) and (ii) a combination of topical corticosteroid (TCS) and NB-UVB compared with TCS alone for localized vitiligo. Methods: Cost-effectiveness analysis alongside a pragmatic, three-arm, placebo-controlled randomized controlled trial with 9 months’ treatment. In total 517 adults and children (aged ≥ 5 years) with active vitiligo affecting < 10% of skin were recruited from secondary care and the community and were randomized 1: 1: 1 to receive TCS, NB-UVB or both. Cost per successful treatment (measured on the Vitiligo Noticeability Scale) was estimated. Secondary cost–utility analyses measured quality-adjusted life-years using the EuroQol 5 Dimensions 5 Levels for those aged ≥ 11 years and the Child Health Utility 9D for those aged 5 to < 18 years. The trial was registered with number ISRCTN17160087 on 8 January 2015. Results: The mean ± SD cost per participant was £775 ± 83·7 for NB-UVB, £813 ± 111.4 for combination treatment and £600 ± 96·2 for TCS. In analyses adjusted for age and target patch location, the incremental difference in cost for combination treatment compared with TCS was £211 (95% confidence interval 188–235), corresponding to a risk difference of 10·9% (number needed to treat = 9). The incremental cost was £1932 per successful treatment. The incremental difference in cost for NB-UVB compared with TCS was £173 (95% confidence interval 151–196), with a risk difference of 5·2% (number needed to treat = 19). The incremental cost was £3336 per successful treatment. Conclusions: Combination treatment, compared with TCS alone, has a lower incremental cost per additional successful treatment than NB-UVB only. Combination treatment would be considered cost-effective if decision makers are willing to pay £1932 per additional treatment success

Plasma metabolites associated with colorectal cancer: A discovery-replication strategy

Colorectal cancer is known to arise from multiple tumorigenic pathways; however, the underlying mechanisms remain not completely understood. Metabolomics is becoming an increasingly popular tool in assessing biological processes. Previous metabolomics research focusing on colorectal cancer is limited by sample size and did not replicate findings in independent study populations to verify robustness of reported findings. Here, we performed a ultrahigh performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-QTOF-MS) screening on EDTA plasma from 268 colorectal cancer patients and 353 controls using independent discovery and replication sets from two European cohorts (ColoCare Study: n = 180 patients/n = 153 controls; the Colorectal Cancer Study of Austria (CORSA) n = 88 patients/n = 200 controls), aiming to identify circulating plasma metabolites associated with colorectal cancer and to improve knowledge regarding colorectal cancer etiology. Multiple logistic regression models were used to test the association between disease state and metabolic features. Statistically significant associated features in the discovery set were taken forward and tested in the replication set to assure robustness of our findings. All models were adjusted for sex, age, BMI and smoking status and corrected for multiple testing using False Discovery Rate. Demographic and clinical data were abstracted from questionnaires and medical records.</p